Haleon plc (HLN.L)

GBp 383.9

(-0.21%)

Market Cap (In GBp)

34.75 Billion

Revenue (In GBp)

11.3 Billion

Net Income (In GBp)

1.04 Billion

Avg. Volume

16.83 Million

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
308.37-400.649
PE
-
EPS
-
Beta Value
0.24
ISIN
GB00BMX86B70
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Brian James McNamara
Employee Count
-
Website
https://www.haleon.com
Ipo Date
2022-07-18
Details
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.